<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>As success of reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT) relies primarily on graft-versus-<z:hpo ids='HP_0001909'>leukemia</z:hpo> (GVL) activity, increased minor HLA disparity in unrelated compared to related donors could have a significant impact on transplant outcomes </plain></SENT>
<SENT sid="1" pm="."><plain>To assess whether use of unrelated donors (URD) engenders more potent GVL in RIC HSCT compared to matched related donors (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>), we retrospectively studied 433 consecutive T-replete 6/6 HLA matched URD (n = 246) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> (n = 187) RIC HSCT for <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> at our institution </plain></SENT>
<SENT sid="2" pm="."><plain>Diseases included: <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (127), non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) (71), <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL) (68), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (64), <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) (40), <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) (25), <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM) (23), <z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>) (12), <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) (7), and other <z:hpo ids='HP_0001909'>leukemia</z:hpo> (1) </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> received uniform fludarabine and intravenous <z:chebi fb="0" ids="28901">busulfan</z:chebi> conditioning, and GVHD prophylaxis with tacrolimus/mini-methroxate (mini-MTX) or tacrolimus/<z:chebi fb="0" ids="9168">sirolimus</z:chebi> ± mini-MTX </plain></SENT>
<SENT sid="4" pm="."><plain>Unrelated donors were younger compared to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> (median donor age: 33 years versus 52 years, P &lt; .0001), and provided larger CD34(+) products (median CD34(+) cells infused: 8.7 × 10(6)/kg versus 7.5 × 10(6)/kg, P = .002) </plain></SENT>
<SENT sid="5" pm="."><plain>Distribution of diseases, disease risk, prior transplant, and cytomegalovirus (CMV) status was similar in both cohorts </plain></SENT>
<SENT sid="6" pm="."><plain>Cumulative incidence of grade II-IV <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD (at day +180), 2-year <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD, and 2-year nonrelapse mortality (NRM) were 20% versus 16%, 55% versus 50%, and 8% versus 6% in URD and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>, respectively (P = NS) </plain></SENT>
<SENT sid="7" pm="."><plain>Cumulative incidence of relapse at 2 years was lower in URD, 52% versus 65% (P = .005) </plain></SENT>
<SENT sid="8" pm="."><plain>With median follow-up of 26.5 and 35.8 months, 2-year progression-free survival (PFS) was significantly better in unrelated donor transplants, 39.5% for URD, and 29% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> (P = .01) </plain></SENT>
<SENT sid="9" pm="."><plain>Overall survival (OS) at 2 years were 56% for URD versus 50% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> (P = .53) </plain></SENT>
<SENT sid="10" pm="."><plain>In multivariable analysis, URD was associated with a lower risk of relapse (hazard ratio [HR] 0.67, P = .002) and superior PFS (HR 0.69, P = .002) </plain></SENT>
<SENT sid="11" pm="."><plain>These results suggest that URD is associated with greater GVL activity than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>, and could have practice changing impact on future donor selection in RIC HSCT </plain></SENT>
</text></document>